The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration (30 day TA).
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
This consultation will run for 2 weeks and will close at 5pm on Thursday 19th December 2024. Take part by visiting the consultations page.